Literature DB >> 2052362

Association of casein kinase II with immunopurified p53.

C P Herrmann1, S Kraiss, M Montenarh.   

Abstract

Viral and cellular oncogene products sometimes activate protein kinases, are protein kinases themselves, or share phosphorylation sequence motifs for different protein kinases. We have recently shown that a protein kinase activity is tightly associated with immunopurified p53. We have now expressed p53 in a baculovirus expression system and characterized this protein kinase activity in more detail. We found that casein could compete with p53 in the kinase reaction. Heparin efficiently inhibited the p53 associated protein kinase whereas the polyamine spermidine stimulated enzymatic activity. A synthetic peptide which was shown to be specifically phosphorylated by casein kinase II blocked the in vitro phosphorylation of p53, whereas a synthetic peptide with a potential phosphorylation site on human p53 at ser 315 was ineffective in blocking the phosphorylation of p53. GTP as well as ATP can be used as a phosphate donor in the in vitro kinase reaction. An antibody directed against casein kinase II coprecipitated p53 from insect cells as well as from mammalian cells. These data strongly indicate that casein kinase II is associated with immunopurified p53 and contributes to the phosphorylation of p53. A mutant p53 with a ser 389 to ala exchange was not phosphorylated in vitro by the p53 associated protein kinase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052362

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable.

Authors:  L McKendrick; D Milne; D Meek
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

2.  Protein kinase CK2 interacts with a multi-protein binding domain of p53.

Authors:  C Götz; P Scholtes; A Prowald; N Schuster; W Nastainczyk; M Montenarh
Journal:  Mol Cell Biochem       Date:  1999-01       Impact factor: 3.396

3.  Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.

Authors:  M S Rodriguez; J M Desterro; S Lain; D P Lane; R T Hay
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

4.  Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53.

Authors:  D M Milne; R H Palmer; D W Meek
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

Review 5.  Nuclear protein phosphorylation and growth control.

Authors:  D W Meek; A J Street
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

6.  Phosphorylation of IkappaBalpha in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability.

Authors:  R Lin; P Beauparlant; C Makris; S Meloche; J Hiscott
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

7.  Contribution of the individual subunits of protein kinase CK2 and of hPrp3p to the splicing process.

Authors:  Janka Dörr; Sabine Kartarius; Claudia Götz; Mathias Montenarh
Journal:  Mol Cell Biochem       Date:  2008-06-14       Impact factor: 3.396

8.  Stabilization and activation of p53 are regulated independently by different phosphorylation events.

Authors:  M V Chernov; C V Ramana; V V Adler; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

9.  Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.

Authors:  J Benn; R J Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53.

Authors:  S J Ullrich; K Sakaguchi; S P Lees-Miller; M Fiscella; W E Mercer; C W Anderson; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.